Smith C Daniel, Stival Alessandro, Howell D Lee, Swafford Vickie
Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
Ann Surg. 2006 May;243(5):579-84; discussion 584-6. doi: 10.1097/01.sla.0000217524.75529.2d.
Heller myotomy has been shown to be an effective primary treatment of achalasia. However, many physicians treating patients with achalasia continue to offer endoscopic therapies before recommending operative myotomy. Herein we report outcomes in 209 patients undergoing Heller myotomy with the majority (74%) undergoing myotomy as secondary treatment of achalasia.
Data on all patients undergoing operative management of achalasia are collected prospectively. Over a 9-year period (1994-2003), 209 patients underwent Heller myotomy for achalasia. Of these, 154 had undergone either Botox injection and/or pneumatic dilation preoperatively. Preoperative, operative, and long-term outcome data were analyzed. Statistical analysis was performed with multiple chi and Mann-Whitney U analyses, as well as ANOVA.
Among the 209 patients undergoing Heller myotomy for achalasia, 154 received endoscopic therapy before being referred for surgery (100 dilation only, 33 Botox only, 21 both). The groups were matched for preoperative demographics and symptom scores for dysphagia, regurgitation, and chest pain. Intraoperative complications were more common in the endoscopically treated group with GI perforations being the most common complication (9.7% versus 3.6%). Postoperative complications, primarily severe dysphagia, and pulmonary complications were more common after endoscopic treatment (10.4% versus 5.4%). Failure of myotomy as defined by persistent or recurrent severe symptoms, or need for additionally therapy including redo myotomy or esophagectomy was higher in the endoscopically treated group (19.5% versus 10.1%).
Use of preoperative endoscopic therapy remains common and has resulted in more intraoperative complications, primarily perforation, more postoperative complications, and a higher rate of failure than when no preoperative therapy was used. Endoscopic therapy for achalasia should not be used unless patients are not candidates for surgery.
已证明贲门肌层切开术是贲门失弛缓症的一种有效的主要治疗方法。然而,许多治疗贲门失弛缓症患者的医生在推荐手术肌层切开术之前仍继续提供内镜治疗。在此我们报告209例行贲门肌层切开术患者的治疗结果,其中大多数(74%)患者的肌层切开术是作为贲门失弛缓症的二线治疗。
前瞻性收集所有接受贲门失弛缓症手术治疗患者的数据。在9年期间(1994 - 2003年),209例患者因贲门失弛缓症接受了贲门肌层切开术。其中,154例患者术前接受过肉毒杆菌毒素注射和/或气囊扩张术。对术前、术中及长期治疗结果数据进行分析。采用多个卡方检验、曼 - 惠特尼U检验以及方差分析进行统计学分析。
在209例因贲门失弛缓症接受贲门肌层切开术的患者中,154例在转诊手术前接受了内镜治疗(仅扩张术100例,仅肉毒杆菌毒素注射33例,两者均接受21例)。两组患者在术前人口统计学特征以及吞咽困难、反流和胸痛的症状评分方面相匹配。内镜治疗组术中并发症更为常见,胃肠道穿孔是最常见的并发症(9.7%对3.6%)。术后并发症,主要是严重吞咽困难和肺部并发症,在内镜治疗后更为常见(10.4%对5.4%)。内镜治疗组中,根据持续性或复发性严重症状定义的肌层切开术失败率,或包括再次肌层切开术或食管切除术在内的额外治疗需求更高(19.5%对10.1%)。
术前内镜治疗的使用仍然很常见,与未使用术前治疗相比,其导致更多的术中并发症,主要是穿孔,更多的术后并发症以及更高的失败率。除非患者不适合手术,否则不应使用内镜治疗贲门失弛缓症。